ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $328 | -47.8% | 29,364 | 0.0% | 0.02% | -44.4% |
| Q2 2023 | $628 | -9.8% | 29,364 | +70.7% | 0.03% | -18.2% |
| Q1 2023 | $696 | -9.3% | 17,204 | +4.4% | 0.03% | -21.4% |
| Q4 2022 | $767 | -99.9% | 16,480 | -29.9% | 0.04% | -43.2% |
| Q3 2022 | $1,219,000 | -11.2% | 23,510 | -19.0% | 0.07% | -28.2% |
| Q2 2022 | $1,372,000 | +4.4% | 29,020 | +57.2% | 0.10% | +19.8% |
| Q1 2022 | $1,314,000 | +371.0% | 18,460 | +457.9% | 0.09% | -16.5% |
| Q2 2019 | $279,000 | -77.9% | 3,309 | -74.9% | 0.10% | -85.7% |
| Q1 2019 | $1,260,000 | -20.8% | 13,186 | -41.3% | 0.72% | +62.2% |
| Q4 2018 | $1,591,000 | +3.9% | 22,465 | +25.3% | 0.44% | +34.5% |
| Q3 2018 | $1,532,000 | +83.0% | 17,922 | +148.2% | 0.33% | +89.7% |
| Q2 2018 | $837,000 | +46.3% | 7,220 | +2.1% | 0.17% | +56.8% |
| Q1 2018 | $572,000 | – | 7,070 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |